Cell-free epigenomes enhanced fragmentomics-based model for early detection of lung cancer

IF 6.8 1区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Clinical and Translational Medicine Pub Date : 2025-02-05 DOI:10.1002/ctm2.70225
Yadong Wang, Qiang Guo, Zhicheng Huang, Liyang Song, Fei Zhao, Tiantian Gu, Zhe Feng, Haibo Wang, Bowen Li, Daoyun Wang, Bin Zhou, Chao Guo, Yuan Xu, Yang Song, Zhibo Zheng, Zhongxing Bing, Haochen Li, Xiaoqing Yu, Ka Luk Fung, Heqing Xu, Jianhong Shi, Meng Chen, Shuai Hong, Haoxuan Jin, Shiyuan Tong, Sibo Zhu, Chen Zhu, Jinlei Song, Jing Liu, Shanqing Li, Hefei Li, Xueguang Sun, Naixin Liang
{"title":"Cell-free epigenomes enhanced fragmentomics-based model for early detection of lung cancer","authors":"Yadong Wang,&nbsp;Qiang Guo,&nbsp;Zhicheng Huang,&nbsp;Liyang Song,&nbsp;Fei Zhao,&nbsp;Tiantian Gu,&nbsp;Zhe Feng,&nbsp;Haibo Wang,&nbsp;Bowen Li,&nbsp;Daoyun Wang,&nbsp;Bin Zhou,&nbsp;Chao Guo,&nbsp;Yuan Xu,&nbsp;Yang Song,&nbsp;Zhibo Zheng,&nbsp;Zhongxing Bing,&nbsp;Haochen Li,&nbsp;Xiaoqing Yu,&nbsp;Ka Luk Fung,&nbsp;Heqing Xu,&nbsp;Jianhong Shi,&nbsp;Meng Chen,&nbsp;Shuai Hong,&nbsp;Haoxuan Jin,&nbsp;Shiyuan Tong,&nbsp;Sibo Zhu,&nbsp;Chen Zhu,&nbsp;Jinlei Song,&nbsp;Jing Liu,&nbsp;Shanqing Li,&nbsp;Hefei Li,&nbsp;Xueguang Sun,&nbsp;Naixin Liang","doi":"10.1002/ctm2.70225","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Lung cancer is a leading cause of cancer mortality, highlighting the need for innovative non-invasive early detection methods. Although cell-free DNA (cfDNA) analysis shows promise, its sensitivity in early-stage lung cancer patients remains a challenge. This study aimed to integrate insights from epigenetic modifications and fragmentomic features of cfDNA using machine learning to develop a more accurate lung cancer detection model.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>To address this issue, a multi-centre prospective cohort study was conducted, with participants harbouring suspicious malignant lung nodules and healthy volunteers recruited from two clinical centres. Plasma cfDNA was analysed for its epigenetic and fragmentomic profiles using chromatin immunoprecipitation sequencing, reduced representation bisulphite sequencing and low-pass whole-genome sequencing. Machine learning algorithms were then employed to integrate the multi-omics data, aiding in the development of a precise lung cancer detection model.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Cancer-related changes in cfDNA fragmentomics were significantly enriched in specific genes marked by cell-free epigenomes. A total of 609 genes were identified, and the corresponding cfDNA fragmentomic features were utilised to construct the ensemble model. This model achieved a sensitivity of 90.4% and a specificity of 83.1%, with an AUC of 0.94 in the independent validation set. Notably, the model demonstrated exceptional sensitivity for stage I lung cancer cases, achieving 95.1%. It also showed remarkable performance in detecting minimally invasive adenocarcinoma, with a sensitivity of 96.2%, highlighting its potential for early detection in clinical settings.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>With feature selection guided by multiple epigenetic sequencing approaches, the cfDNA fragmentomics-based machine learning model demonstrated outstanding performance in the independent validation cohort. These findings highlight its potential as an effective non-invasive strategy for the early detection of lung cancer.</p>\n </section>\n \n <section>\n \n <h3> Keypoints</h3>\n \n <div>\n <ul>\n \n <li>Our study elucidated the regulatory relationships between epigenetic modifications and their effects on fragmentomic features.</li>\n \n <li>Identifying epigenetically regulated genes provided a critical foundation for developing the cfDNA fragmentomics-based machine learning model.</li>\n \n <li>The model demonstrated exceptional clinical performance, highlighting its substantial potential for translational application in clinical practice.</li>\n </ul>\n </div>\n </section>\n </div>","PeriodicalId":10189,"journal":{"name":"Clinical and Translational Medicine","volume":"15 2","pages":""},"PeriodicalIF":6.8000,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ctm2.70225","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/ctm2.70225","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Lung cancer is a leading cause of cancer mortality, highlighting the need for innovative non-invasive early detection methods. Although cell-free DNA (cfDNA) analysis shows promise, its sensitivity in early-stage lung cancer patients remains a challenge. This study aimed to integrate insights from epigenetic modifications and fragmentomic features of cfDNA using machine learning to develop a more accurate lung cancer detection model.

Methods

To address this issue, a multi-centre prospective cohort study was conducted, with participants harbouring suspicious malignant lung nodules and healthy volunteers recruited from two clinical centres. Plasma cfDNA was analysed for its epigenetic and fragmentomic profiles using chromatin immunoprecipitation sequencing, reduced representation bisulphite sequencing and low-pass whole-genome sequencing. Machine learning algorithms were then employed to integrate the multi-omics data, aiding in the development of a precise lung cancer detection model.

Results

Cancer-related changes in cfDNA fragmentomics were significantly enriched in specific genes marked by cell-free epigenomes. A total of 609 genes were identified, and the corresponding cfDNA fragmentomic features were utilised to construct the ensemble model. This model achieved a sensitivity of 90.4% and a specificity of 83.1%, with an AUC of 0.94 in the independent validation set. Notably, the model demonstrated exceptional sensitivity for stage I lung cancer cases, achieving 95.1%. It also showed remarkable performance in detecting minimally invasive adenocarcinoma, with a sensitivity of 96.2%, highlighting its potential for early detection in clinical settings.

Conclusions

With feature selection guided by multiple epigenetic sequencing approaches, the cfDNA fragmentomics-based machine learning model demonstrated outstanding performance in the independent validation cohort. These findings highlight its potential as an effective non-invasive strategy for the early detection of lung cancer.

Keypoints

  • Our study elucidated the regulatory relationships between epigenetic modifications and their effects on fragmentomic features.
  • Identifying epigenetically regulated genes provided a critical foundation for developing the cfDNA fragmentomics-based machine learning model.
  • The model demonstrated exceptional clinical performance, highlighting its substantial potential for translational application in clinical practice.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
无细胞表观基因组增强片段组学的肺癌早期检测模型
肺癌是导致癌症死亡的主要原因,因此需要创新的非侵入性早期检测方法。尽管无细胞DNA (cfDNA)分析显示出希望,但其在早期肺癌患者中的敏感性仍然是一个挑战。本研究旨在利用机器学习整合cfDNA表观遗传修饰和片段组学特征的见解,以开发更准确的肺癌检测模型。为了解决这一问题,我们进行了一项多中心前瞻性队列研究,参与者包括可疑的恶性肺结节和来自两个临床中心的健康志愿者。使用染色质免疫沉淀测序、亚硫酸还原测序和低通全基因组测序分析血浆cfDNA的表观遗传和片段组学特征。然后使用机器学习算法来整合多组学数据,帮助开发精确的肺癌检测模型。结果cfDNA片段组学中与癌症相关的变化在无细胞表观基因组标记的特定基因中显著富集。共鉴定了609个基因,并利用相应的cfDNA片段组学特征构建了集合模型。该模型的灵敏度为90.4%,特异性为83.1%,在独立验证集中的AUC为0.94。值得注意的是,该模型对I期肺癌的敏感性达到了95.1%。它在检测微创腺癌方面也表现出色,灵敏度为96.2%,突出了其在临床早期发现的潜力。结论基于cfDNA片段组学的机器学习模型在多种表观遗传测序方法的指导下进行特征选择,在独立验证队列中表现出色。这些发现突出了它作为一种有效的非侵入性肺癌早期检测策略的潜力。我们的研究阐明了表观遗传修饰及其对片段组学特征的影响之间的调控关系。识别表观遗传调控基因为开发基于cfDNA片段组学的机器学习模型提供了重要的基础。该模型表现出优异的临床表现,突出了其在临床实践中转化应用的巨大潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
15.90
自引率
1.90%
发文量
450
审稿时长
4 weeks
期刊介绍: Clinical and Translational Medicine (CTM) is an international, peer-reviewed, open-access journal dedicated to accelerating the translation of preclinical research into clinical applications and fostering communication between basic and clinical scientists. It highlights the clinical potential and application of various fields including biotechnologies, biomaterials, bioengineering, biomarkers, molecular medicine, omics science, bioinformatics, immunology, molecular imaging, drug discovery, regulation, and health policy. With a focus on the bench-to-bedside approach, CTM prioritizes studies and clinical observations that generate hypotheses relevant to patients and diseases, guiding investigations in cellular and molecular medicine. The journal encourages submissions from clinicians, researchers, policymakers, and industry professionals.
期刊最新文献
P2X7R deficiency alleviates cardiac senescence by enhancing mitophagy via the HuR/TRIM26/NR4A1 axis. Unveiling miR-451a and miR-142-3p as prognostic markers in non-small cell lung cancer via small extracellular vesicle liquid biopsy. Single-cell multi-omics analysis of the tumour microenvironment for colorectal cancer liver metastasis. Clonal haematopoiesis in chronic lymphocytic leukaemia: Biology, inflammaging and clinical implications in the era of targeted therapy. CMA-mediated USP9X degradation promotes SHH medulloblastoma progression by facilitating SUFU ubiquitination.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1